Pradaxa® (dabigatran etexilate) – first new oral anticoagulant in nearly 60 years receives final NICE recommendation for stroke prevention in atrial fibrillation in the UK 1

- For NON-US, NON-UK & NON- Canadian Healthcare Media Only

Ingelheim, Germany, 16 March 2011 – On 15 March, the National Institute for Health and Clinical Excellence (NICE) has issued final guidance recommending the novel oral anticoagulant, Pradaxa® (dabigatran etexilate) 2 as a cost-effective option for the prevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation (AF) and one or more risk factors. 1

This landmark decision means Pradaxa® must now be made available for use by the UK National Health Service (NHS) and that patients have the right to receive it if clinicians deem it clinically appropriate.


More in Home